Generating a mirror-image monobody targeting MCP-1 via TRAP display and chemical protein synthesis
Biologically produced protein drugs are generally susceptible to degradation by proteases and often exhibit immunogenicity. To address this issue, mirror-image peptide/protein binders consisting of D-amino acids have been developed so far through the mirror-image phage display technique. Here, we develop a mirror-image protein binder derived from a monobody, one of the promising protein scaffolds, utilizing two notable technologies: chemical protein synthesis and TRAP display, an improved version of mRNA display. A sequential workflow of initial screening followed by affinity maturation, facilitated by TRAP display, generates an L-monobody with high affinity (K<sub>D</sub> = 1.3 nM) against monocyte chemoattractant protein-1 (MCP-1) D-enantiomer. The chemically synthesized D-monobody demonstrates strong and specific binding to L-MCP-1 and exhibits pharmaceutically favorable properties such as proteolytic resistance, minimal immune response, and a potent inhibitory effect on MCP-1-induced cell migration. This study elevates the value of mirror-image peptide/protein binders as an alternative modality in drug discovery.
Authors
- Naoya Iwamoto (ORCID: https://orcid.org/0009-0003-6664-8117)
- Shinya Oishi (ORCID: https://orcid.org/0000-0002-2833-2539)
- Gosuke Hayashi (ORCID: https://orcid.org/0000-0001-6853-2706)
- Sayaka Miura (ORCID: https://orcid.org/0000-0001-9881-2848)
- Hiroshi Murakami (ORCID: https://orcid.org/0000-0003-2089-9263)
- Motohiro Nonaka (ORCID: https://orcid.org/0000-0002-8487-6485)
- Katsuaki Higashi
- S. Suzuki (ORCID: https://orcid.org/0009-0002-1296-0693)
- Toshinori Naito
- Yusuke Usui
- Mika Bando-Shimizu
Institutions
- Kyoto University (JP)
- Kyoto Pharmaceutical University (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Nature Communications
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1038/s41467-024-54902-x
- Citations
- 11
- Primary Topic
- Chemical Synthesis and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.57
Funders
- Japan Agency for Medical Research and Development
- Tokyo Biochemical Research Foundation
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Japan Society for the Promotion of Science
- Precursory Research for Embryonic Science and Technology